Last Updated: November 12, 2026

CENTANY Drug Patent Profile

Name: CENTANY Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CENTANY?
What are the global sales for CENTANY?
What is Average Wholesale Price for CENTANY?

Summary for CENTANY

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	2
Patent Applications:	6,657
What excipients (inactive ingredients) are in CENTANY?	CENTANY excipients list
DailyMed Link:	CENTANY at DailyMed

Drug patent expirations by year for CENTANY

Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cook Children's Medical Center	Phase 2
University of Texas Southwestern Medical Center	Phase 2
National Jewish Health	Phase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CENTANY

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	6,013,657	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Canada	2259764	COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN)	⤷ Start Trial
Germany	69900561		⤷ Start Trial
European Patent Office	0933081	Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin)	⤷ Start Trial
Spain	2165723		⤷ Start Trial
Israel	123143	PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

DrugChatter Q&A for CENTANY

Is Centany the same as Mupirocin?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.